Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis 1Q11

Pharmaceuticals sales were up 7% to $7.8 billion. Diovan sales were down 3% to $1.4 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis 1Q11

1Q Revenues: $14.0 billion (+16%)

1Q Earnings: $3.4 billion (+2%)

Comments: Pharmaceuticals sales were up 7% to $7.8 billion. Diovan sales were down 3% to $1.4 billion. Exforge sales were $261 million (+28%). Tekturna/Rasilez sales were $131 million (+47%). Galvus sales were up 74% to $132 million. Gleevec/Glivec sales were $1.1 billion (+4%). Lucentis sales were $444 million (+22%). Sales of Xolair were up 34% to $107 million. Sales at the Sandoz unit were $2.3 billion (+16%), driven by recently launched products, enoxaparin (generic Lovenox) and gemcitabine (generic Gemzar), as well as accelerating biosimilars growth outside Germany. Vaccines & Diagnostics sales were down 73% to $371 million due to 2010 A(H1N1) pandemic flu vaccine sales ($1.1 billion). Consumer Health sales were up 11% to $1.6 billion. Alcon sales were $1.9 billion (+12%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics